Movement Alert｜GENSCRIPT BIO Intraday Decline 3.22% in Regular Trading, Pharmaceutical Sector Under Correction Pressure

Market Focus09:31

On October 8, GENSCRIPT BIO fell 3.22% in regular trading, trading at HK$41.44 with a turnover of HK$78.392 million. The stock extended weakness following a sharp 12.70% drop in the previous session, reflecting broader correction pressure across the pharmaceutical sector.

The pullback was amplified by overnight weakness in US pharmaceutical stocks, after Allist Pharmaceuticals' furmonertinib failed a global Phase 3 trial, sending its shares down 46.98% and weighing on sentiment across Hong Kong's biotech complex. GENSCRIPT BIO had surged nearly 270% from early July to October 6, and some institutions moved to lock in profits at elevated levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment